Wedbush Maintains Outperform on Maze Therapeutics, Raises Price Target to $49

Benzinga · 1d ago
Wedbush analyst Laura Chico maintains Maze Therapeutics (NASDAQ:MAZE) with a Outperform and raises the price target from $48 to $49.